View Document Preview and Link Open Document File Size: 513,38 KB Share Result on Facebook
City East Hanover / Hanover / / Company Novartis Pharmaceuticals Corporation / Medical Affairs Novartis Pharmaceuticals Corporation / / Country United States / / Event FDA Phase / / Facility One Health Plaza / Novartis Pharmaceuticals Corporation One Health Plaza / / IndustryTerm Healthcare professionals / treatment of women with irritable bowel syndrome / / MedicalCondition abdominal pain / clinically significant diarrhea / cholecystitis / Zelnorm patients reporting diarrhea / severe diarrhea / ischemic colitis / syncope / diarrhea / Oddi spasm / Zelnorm-Induced Diarrhea / bloody diarrhea / irritable bowel syndrome / constipation / Hypokalemia / PRECAUTIONS Ischemic Colitis Ischemic colitis / much diarrhea / hypotension / / MedicalTreatment rehydration / / Organization FDA / / Person Stephen R. Cunningham / Alan L. Bess / / / Position Vice President US Clinical Development / physician / Vice President Clinical Safety and Epidemiology Stephen R. Cunningham / Vice President Clinical Safety and Epidemiology / / Product Zelnorm / Zelnorm® (tegaserod maleate) tablets / / ProvinceOrState New Jersey / / URL http / SocialTag 
Novartis Pharmaceuticals Corporation One Health Plaza East Hanover, NJ[removed]Tel[removed]April 26, 2004